Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 50, Issue 7, 2004, Pages 2130-2139

  Jansen, Gerrit ^a   Van Der Heijden, Joost ^a   Oerlemans, Ruud ^a   Lems, Willem F ^a   Ifergan, Ilan ^b   Scheper, Rik J ^a   Assaraf, Yehuda G ^b   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; REDUCED FOLATE CARRIER; SALAZOSULFAPYRIDINE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRANSPORT KINETICS; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL TRANSPORT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FOLIC ACID; HUMANS; LEUCOVORIN; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; P-GLYCOPROTEIN; SULFASALAZINE;

EID: 3142750489     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20375     Document Type: Article

References (68)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93.
3. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
4. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-9.
5. Fathy N, Furst DE. Combination therapy for autoimmune diseases: the rheumatoid arthritis model. Springer Semin Immunopathol 2001;23:5-26.
6. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
7. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulfasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002;41:892-8.
8. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
9. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002;252:475-96.
10. Haagsma CJ, Russel FG, Vree TB, van Riel PL, van de Putte LB. Combination of methotrexate and sulfasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996;42:195-200.
11. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulfasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
12. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
13. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
14. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
15. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, Oppenraaij-Emmerzaal D, et al. Influence of sulfasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
16. Krogh JM, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulfasalazine for arthritis. Scand J Clin Lab Invest 1996;56:421-9.
17. Grindulis KA, McConkey B. Does sulfasalazine cause folate deficiency in rheumatoid arthritis? Scand J Rheumatol 1985;14: 265-70.
18. Logan EC, Williamson LM, Ryrie DR. Sulfasalazine associated pancytopenia may be caused by acute folate deficiency. Gut 1986;27:868-72.
19. Swinson CM, Perry J, Lumb M, Levi AJ. Role of sulfasalazine in the aetiology of folate deficiency in ulcerative colitis. Gut 1981;22: 456-61.
20. Shiroky JB. Unsubstantiated "risk" of antifolate toxicity with combination methotrexate and sulfasalazine therapy. Arthritis Rheum 1993;12:1757-8.
21. Morgan SL, Baggott JE, Alarcón GS. Methotrexate and sulfasalazine combination therapy: is it worth the risk? Arthritis Rheum 1993;36:281-2.
22. Longstreth GF, Green R. Folate status in patients receiving maintenance doses of sulfasalazine. Arch Intern Med 1983;143: 902-4.
23. Selhub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. J Clin Invest 1978;61:221-4.
24. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282:197-202.
25. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 1981;305: 1513-7.
26. Franklin JL, Rosenberg HH. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology 1973;64:517-25.
27. Zimmerman J. Drug interactions in intestinal transport of folic acid and methotrexate: further evidence for the heterogeneity of folate transport in the human small intestine. Biochem Pharmacol 1992;44:1839-42.
28. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol Pharmacol 1995;48:459-71.
29. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999;19:91-122.
30. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 1971;186:400-22.
31. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
32. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates. In: Jackman AL, editor. Anticancer drug development guide: antifolate drugs in cancer therapy. Humana Press: Totowa (NJ); 1999. p. 293-321.
33. Bertino JR. Karnofsky memorial lecture: ode to methotrexate. J Clin Oncol 1993;11:5-14,
34. Cronstein BN, Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
35. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
36. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003;62:4-9.
37. Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000;110: 791-800.
38. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem J 2002;367:741-50.
39. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
40. Jansen G, Pieters R. The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates. Drug Resist Updat 1998;1:211-8.
41. Jansen G, Kathmann I, Rademaker BC, Braakhuis BJ, Westerhof GR, Rijksen G, et al. Expression of a folate binding protein in L1210 cells grown in low folate medium. Cancer Res 1989;49: 1959-63.
42. Mauritz R, Bekkenk MW, Rots MG, Pieters R, Mini E, Van Zantwijk CH, et al. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 1998; 4:2399-410.
43. Jansen G, Westerhof GR, Jarmuszewski MJ, Kathmann I, Rijksen G, Schornagel JH. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier: selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem 1990;265:18272-7.
44. Jansen G, Mauritz RM, Assaraf YG, Sprecher H, Drori S, Kathmann I, et al. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and -resistant leukemia cells. Adv Enzyme Regul 1997;37:59-76.
45. Drori S, Sprecher H, Shemer G, Jansen G, Goldman ID, Assaraf YG. Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur J Biochem 2000;267:690-702.
46. Van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann GA, et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα. Ann Rheum Dis 2004;63:138-43.
47. Van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann GA, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004;63: 131-7.
48. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000;60: 5269-77.
49. Smedegard G, Bjork J. Sulfasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:7-15.
50. Lin JT, Bertino JR. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 1991;9:159-72.
51. Hum M, Holcenberg JS, Tkaczewski I, Weaver JW, Wilson J, Kamen BA. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? Clin Cancer Res 1998;4:2981-4.
52. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
53. Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann GA, et al. Loss of multidrug resistance protein 1 (MRP1) expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 2003;278:6680-6.
54. Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, et al. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol 2003;65:765-71.
55. Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 2003;64:220-7.
56. Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;63: 105-15.
57. Sirotnak FM, Moccio DM, Goutas LJ, Kelleher LE, Montgomery JA. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res 1982;42:924-8.
58. Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
59. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
60. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-43.
61. Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol 2003;32:325-36.
62. Said HM, Nguyen TT, Dyer DL, Cowan KH, Rubin SA. Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. Biochim Biophys Acta 1996;1281:164-72.
63. Nguyen TT, Dyer DL, Dunning DD, Rubin SA, Grant KE, Said HM. Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. Gastroenterology 1997;112: 783-91.
64. Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001;281: C1579-86.
65. Assaraf YG, Sierra EE, Babani S, Goldman ID. Inhibitory effects of prostaglandin A1 on membrane transport of folates mediated by both the reduced folate carrier and ATP-driven exporters. Biochem Pharmacol 1999;58:1321-7.
66. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3-23.
67. Jansen G, Scheper RJ, Dijkmans BAC. Chloroquine resistance in human CEM (T) cells is mediated by multidrug resistance protein 1 [abstract]. Ann Rheum Dis 2001;60:89.
68. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol 1998;56:733-42.